https://www.pfizer.com/news/press-release/press-release-detail/padcevtm-plus-keytrudar-significantly-improves-survival
0
0
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility - Pfizer
12/17/25 at 12:16pm
Organization
Pfizer.com
60 words
0
Comments
TOKYO AND NEW YORK, December 17, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also kno…
You are the first to view
Create an account or login to join the discussion